Immutep Ltd ADR (IMMP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immutep Ltd ADR stock (IMMP) is currently trading at $0.36. Immutep Ltd ADR PS ratio (Price-to-Sales) is 7.34. Analyst consensus price target for IMMP is $1.00. WallStSmart rates IMMP as Sell.
- IMMP PE ratio analysis and historical PE chart
- IMMP PS ratio (Price-to-Sales) history and trend
- IMMP intrinsic value — DCF, Graham Number, EPV models
- IMMP stock price prediction 2025 2026 2027 2028 2029 2030
- IMMP fair value vs current price
- IMMP insider transactions and insider buying
- Is IMMP undervalued or overvalued?
- Immutep Ltd ADR financial analysis — revenue, earnings, cash flow
- IMMP Piotroski F-Score and Altman Z-Score
- IMMP analyst price target and Smart Rating
Immutep Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Immutep Ltd ADR (IMMP) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Immutep Ltd ADR (IMMP) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 91.50% year-over-year
Supporting Valuation Data
Immutep Ltd ADR (IMMP) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 2.11%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 7.3x annual revenue
Supporting Valuation Data
Immutep Ltd ADR (IMMP) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.81) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 91.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Some valuation metrics including Price/Sales (7.34) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -61.90%, Operating Margin at -764.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -61.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 91.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMMP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMMP's Price-to-Sales ratio of 7.34x trades at a deep discount to its historical average of 32.53x (0th percentile). The current valuation is 86% below its historical high of 52.02x set in Feb 2026, and 0% above its historical low of 7.34x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~52.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immutep Ltd ADR (IMMP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immutep Ltd ADR is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 8M with 92% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 92% YoY, reaching 8M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 67M in cash.
Free cash flow is -28M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Immutep Ltd ADR maintain 92%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.64, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immutep Ltd ADR.
Bottom Line
Immutep Ltd ADR is a high-conviction growth story with revenue accelerating at 92% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:22:00 AM
About Immutep Ltd ADR(IMMP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia.